EXCLI Journal 2024;23:1356-1374 – ISSN 1611-2156
Received: June 06, 2024, accepted: November 05, 2024, published: November 12, 2024

Supplementary data to:

Original article:

THE SESQUITERPENE ALCOHOL FARNESOL MITIGATES CADMIUM HEPATOTOXICITY BY ATTENUATING OXIDATIVE STRESS AND NF-κB/NLRP3 INFLAMMASOME AXIS AND UPREGULATING PPARγ IN RATS

Reem S. Alruhaimi[1], Emad H.M. Hassanein[2], Sulaiman M. Alnasser[3], Mohammed A. Alzoghaibi[4], Omnia A.M. Abd El-Ghafar[5], Mostafa K. Mohammad[6], Ibrahim Elbagory[7], Ayman M. Mahmoud[8,9]*

[1] Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia
[2] Department of Pharmacology & Toxicology, Faculty of Pharmacy, Al-Azhar University-Assiut Branch, Assiut 71524, Egypt
[3] Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Qassim 51452, Saudi Arabia
[4] Physiology Department, College of Medicine, King Saud University, Riyadh, 11461, Saudi Arabia
[5] Department of Pharmacology and Toxicology, Faculty of Pharmacy, Nahda University, Beni-Suef 62764, Egypt
[6] Department of Pharmacology and Toxicology, Faculty of Pharmacy, Badr University in Assiut, New Nasser City, West of Assiut, Assiut 71523, Egypt
[7] Department of Pharmaceutics, Faculty of Pharmacy, Northern Border University, Rafha 76321, Saudi Arabia
[8] Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester M1 5GD, UK
[9] Molecular Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, Beni-Suef 62514, Egypt

* **Corresponding author:** Ayman M. Mahmoud, Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester M1 5GD, UK. E-Mail: a.mahmoud@mmu.ac.uk

https://dx.doi.org/10.17179/excli2024-7488

EXCLI Journal 2024;23:1356-1374 – ISSN 1611-2156
Received: June 06, 2024, accepted: November 05, 2024, published: November 12, 2024

Supplementary Table 1: Raw data of the parameters in Figure 1, 3, 4, 6, 7 and 8

		Group I	Group II	Group III	Group IV
Figure 1	ALT	19	15	53	22
		17	15	61	25
		19	20	60	30
		23	18	67	27
		21	17	78	19
		22	13	73	20
	AST	42	41	173	51
		51	46	187	48
		37	48	200	55
		50	51	217	63
		59	54	233	59
		46	36	251	45
	ALP	71	67	197	90
		84	66	251	85
		91	94	237	81
		79	81	222	98
		94	82	284	102
		101	67	268	107
	LDH	191	204	559	292
		196	229	662	314
		194	236	746	338
		220	260	682	355
		225	225	808	248
		224	199	910	355
	Albumin	2.2	3.0	1.1	2.3
		2.3	2.3	1.2	2.6
		2.4	2.7	1.3	1.9
		2.7	2.4	1.1	1.8
		3.0	2.7	1.4	2.2
		2.8	2.9	1.6	2.1
Figure 3	MDA	16.1	19.8	50.4	18.3
		22.4	18.1	35.6	20.0
		14.8	16.5	42.6	29.3
		18.5	17.2	57.9	28.8
		25.8	12.6	40.9	22.4
		17.1	14.1	48.9	24.1
	NO	21.2	25.6	52.0	33.0
		25.8	20.4	69.4	39.4
		27.1	27.0	61.0	41.0
		29.0	19.0	72.0	31.6
		22.9	22.5	64.6	35.2
		20.0	23.2	58.0	34.5
	GSH	19.9	18.7	8.7	17.1
		18.3	18.0	9.5	20.6
		22.5	23.3	10.6	18.0
		23.0	24.3	11.1	16.6
		18.9	21.4	9.1	14.3
		24.1	26.1	12.5	18.0
	SOD	12.0	14.4	4.7	10.1

		8.7	15.1	5.4	12.3
		9.5	10.3	6.4	13.3
		12.7	10.8	5.0	9.3
		9.2	12.6	5.7	8.2
		10.0	12.1	6.8	8.1
	CAT	9.4	10.6	2.6	9.1
		10.9	11.6	3.8	10.2
		11.4	9.8	4.5	8.6
		11.1	12.4	3.1	10.7
		12.9	13.7	4.5	12.1
		9.7	11.5	5.3	10.2
	GPX	13.5	17.1	6.6	12.5
		15.6	14.9	7.1	14.9
		16.2	15.8	5.2	11.1
		14.9	18.8	7.2	13.8
		17.2	16.4	7.8	16.0
		17.8	17.0	5.7	12.2
Figure 4	**NF-kB p65**	31.80	28.00	74.00	51.00
		37.00	27.15	79.90	45.00
		28.00	36.00	86.00	45.60
		32.20	41.40	98.90	53.25
		35.65	32.20	85.10	58.65
		42.55	31.05	90.85	51.75
	NLRP3	114	96	215	141
		107	111	245	127
		86	102	190	121
		105	89	165	105
		91	90	231	155
		97	84	210	118
	ASC	104	105	236	184
		91	114	219	141
		108	93	220	136
		95	89	205	129
		117	90	274	169
		85	96	275	155
	Caspase-1	87	105	471	121
		102	112	512	148
		121	116	425	151
		111	91	385	136
		84	88	554	174
		95	95	520	155
	IL-1B	14.9	18.6	43.3	35.7
		22.7	20.0	59.8	32.8
		15.8	13.3	52.2	24.9
		16.7	12.8	51.1	20.3
		20.3	15.4	47.9	18.4
		14.1	16.1	44.2	22.9
Figure 6	**TNF-a**	20.5	16.8	74.7	33.2
		18.6	22.7	53.3	33.6
		25.7	19.2	55.9	43.7
		21.8	17.4	63.9	30.2

		20.3	14.5	46.5	37.9
		16.5	16.5	62.3	29.7
	IL-6	11.0	8.1	40.1	15.4
		12.2	12.8	47.3	22.1
		9.7	13.5	45.4	14.3
		13.7	10.4	38.5	18.5
		9.8	9.4	35.5	17.2
		12.2	11.8	41.9	14.6
	iNOS	106	88	265	125
		109	95	310	131
		98	106	289	94
		89	89	239	115
		115	108	198	97
		83	92	227	136
	Caspase-3	87.5	104	540	141
		94	96	410	126
		114	88	398	135
		97	91	432	123
		85.5	93	591	152
		122	83	425	189
Figure 7	**TGF-B**	106	85	380	141
		95	102	300	163
		116	90	420	175
		83	115	350	189
		108	98	365	174
		92	107	451	158
	pSmad3/Smad3	114	88	185	95
		89	95	221	111
		94	92	169	120
		104	109	174	135
		102	94	188	131
		97	98	151	108
	SMA	88	106	480	121
		94	89	380	135
		108	97	365	141
		99	86	392	97
		114	87	408	112
		97	102	426	106
Figure 8	**PPARg**	118	121	41	79
		104	115	29	85
		85	135	45	81
		93	122	35	71
		105	98	28	82
		95	116	36	78

EXCLI Journal 2024;23:1356-1374 – ISSN 1611-2156
Received: June 06, 2024, accepted: November 05, 2024, published: November 12, 2024

Uncropped blots
NLRP3



ASC



Cleaved caspase-1



EXCLI Journal 2024;23:1356-1374 – ISSN 1611-2156
Received: June 06, 2024, accepted: November 05, 2024, published: November 12, 2024

B-actin



TGF-B



Smad3



EXCLI Journal 2024;23:1356-1374 – ISSN 1611-2156
Received: June 06, 2024, accepted: November 05, 2024, published: November 12, 2024

p-Smad3



α-SMA



B-actin